arrow
J

Jennifer F. Tseng

city of hope comprehensive cancer center
H指数:42
被引数:6,602

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial

更正:ASO视觉摘要:I-SPY2试验中接受新辅助系统性治疗的高风险乳腺癌年轻女性的手术治疗

2026-09-050
PRE
Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial

更正:I-SPY2试验中接受新辅助系统性治疗的年轻高风险乳腺癌患者的手术治疗

2026-09-030
OA
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial

I-SPY2试验中接受新辅助系统性治疗的年轻高风险乳腺癌患者的手术治疗

2026-08-030
OA
ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial

ASO视觉摘要:I-SPY2试验中接受新辅助系统性治疗的高危年轻女性乳腺癌患者的手术治疗

2026-07-310
PRE
International Consensus on Axillary Staging After Neoadjuvant Chemotherapy in Node-positive Breast Cancer

国际共识:在腋窝分期和术前化疗后的淋巴结阳性乳腺癌

2026-04-150
PRE
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

ASO视觉摘要:新辅助化疗后至手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-290
PRE
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

新辅助化疗后手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-230
PRE
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-141
PRE
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan联合durvalumab治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-144
PRE
ASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
2024-08-130
PRE
ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial
2024-08-030
PRE
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial
2024-07-090
PRE
The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts
2022-02-150
PRE
ASO Visual Abstract: Extremity Soft Tissue Sarcoma-A Multi-institutional Validation of Prognostic Nomograms
2022-01-280
PRE
Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms
2022-01-1113
PRE